LC
KZR

Lindbrook Capital’s Kezar Life Sciences KZR Stock Holding History

Lindbrook Capital’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-42
Closed -$1.3K – 2801
2023
Q1 		$1.3K Buy
42
+29
+223% +$1.68K ﹤0.01% 2398
2022
Q4 		$901 Sell
13
-2
-13% -$148 ﹤0.01% 2484
2022
Q3 		$1K Buy
+15
New +$1.46K ﹤0.01% 2382

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Lindbrook Capital's KZR Position: Q2 2023 in Review

Lindbrook Capital sold out of Kezar Life Sciences (KZR) in Q2 2023, closing a stake of 42 shares — an estimated $1.3K sold.

Lindbrook Capital first reported a position in KZR in Q3 2022 and held it in 3 quarters. The position peaked at $1.3K in Q1 2023. 104 funds tracked by Wall St. Rank hold KZR as of Q2 2023.

  • Lindbrook Capital reported no remaining Kezar Life Sciences position as of Q2 2023 after selling out during the quarter.
  • Lindbrook Capital sold 42 Kezar Life Sciences shares in Q2 2023, an estimated $1.3K.
  • Lindbrook Capital first reported a position in Kezar Life Sciences in Q3 2022 and held it in 3 quarters.
  • Lindbrook Capital's Kezar Life Sciences position peaked at $1.3K in Q1 2023.
  • 104 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2023.

Based on Lindbrook Capital's 13F filing for Q2 2023, filed 31 Jul 2023.